Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

BMC Infectious Diseases

Volumn 8, Issue , 2008, Pages

  Ruelle, Jean ^a   Roman, François ^b   Vandenbroucke, Anne Thérèse ^a   Lambert, Christine ^b   Fransen, Katrien ^c   Echahidi, Fedoua ^d   Piérard, Denis ^d   Verhofstede, Chris ^e   Van Laethem, Kristel ^f   Delforge, Marie Luce ^g   Vaira, Dolorès ^h   Schmit, Jean Claude ^b   Goubau, Patrick ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Retrovirology Laboratory Luxembourg   (Luxembourg)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e GHENT UNIVERSITY   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g ERASME HOSPITAL   (Belgium)

^h UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ARGININE; ATAZANAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; GLUTAMINE; INDINAVIR; ISOLEUCINE; LAMIVUDINE; LEUCINE; LOPINAVIR PLUS RITONAVIR; LYSINE; METHIONINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; VALINE; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BELGIUM; CD4 LYMPHOCYTE COUNT; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; FEMALE; GENETIC CODE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; LUXEMBOURG; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS; TREATMENT FAILURE; VIRUS LOAD; VIRUS TRANSMISSION; AFRICA; CHEMISTRY; CLASSIFICATION; DRUG EFFECT; ETHNOLOGY; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; MUTATION; POLYMERASE CHAIN REACTION; REGISTER; VIROLOGY;

ADULT; AFRICA, WESTERN; AGED; ANTI-RETROVIRAL AGENTS; BELGIUM; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-2; HUMANS; LUXEMBOURG; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; REGISTRIES; RNA, VIRAL; VIRAL LOAD;

EID: 42249099057     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-8-21     Document Type: Article

References (49)

1. Clavel F Mansinho K Chamaret S Guetard D Favier V Nina J Santos-Ferreira MO Champalimaud JL Montagnier L Human immunodeficiency virus type 2 infection associated with AIDS in West Africa N Engl J Med 1987, 316:1180-1185. 3472076
2. Marlink R Kanki P Thior I Travers K Eisen G Siby T Traore I Hsieh CC Dia MC Gueye EH Hellinger J Guèye-Ndiaye A Sankalé JL Ndoye I Mboup S Essex M Reduced rate of disease development after HIV-2 infection as compared to HIV-1 Science 1994, 265:1587-1590. 10.1126/ science.7915856 7915856
3. De Cock KM Adjorlolo G Ekpini E Sibailly T Kouadio J Maran M Brattegaard K Vetter KM Doorly R Gayle HD Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic JAMA 1993, 270:2083-2086. 10.1001/ jama.270.17.2083 8147962
4. Simon F Matheron S Tamalet C Loussert-Ajaka I Bartczak S Pépin JM Dhiver C Gamba E Elbim C Gastaut JA Saimot A Brun-Vézinet F Cellular and plasma viral load in patients infected with HIV-2 AIDS 1993, 7:1411-1417. 10.1097/00002030-199311000-00002 7904166
5. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. DHHS http://aidsinfo.nih.gov/guidelines Revised May 4, 2006.
6. Ren J Bird LE Chamberlain PP Stewart-Jones GB Stuart DI Stammers DK Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors Proc Natl Acad Sci USA 2002, 99:14410-14415. 137897 12386343 10.1073/pnas.222366699
7. Witvrouw M Pannecouque C Switzer WM Folks TM De Clercq E Heneine W Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis Antivir Ther 2004, 9:57-65. 15040537
8. Descamps D In vitro phenotypic susceptibility of HIV-2 clinical isolates to protease inhibitors: Amprenavir, atazanavir, lopinavir and tipranavir [abstract 93] XV International HIV drug resistance workshop: Basic principles and clinical implications: 13-17 June 2006; Sitges, Spain
9. Ntemgwa M Brenner BG Oliveira M Moisi D Wainberg MA Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors Antimicrob Agents Chemother 2007, 51:604-610. 1797771 17116674 10.1128/ AAC.00870-06
10. Rodés B Sheldon J Toro C Jiménez V Alvarez A Soriano V Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy J Antimicrob Chemother 2006, 57:709-713. 10.1093/jac/dkl034 16464891
11. Adjé-Touré CA Cheingsong R Garcia-Lerma JG Eholié S Borget MY Bouchez JM Otten RA Maurice C Sassan-Morokro M Ekpini RE Nolan M Chorba T Heneine W Nkengasong JN Antiretroviral therapy in HIV-2-infected patients: Changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire AIDS 2003, (Suppl 3):S49-54.
12. Desbois D Peytavin G Matheron S Damond F Collin G Bénard A Campa P Chêne G Brun-Vézinet F Diane Descamps The French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2) Phenotypic Susceptibility in vitro to Amprenavir, Atazanavir, Darunavir, Lopinavir, and Tipranavir of HIV-2 Clinical Isolates from the French ANRS HIV-2 Cohort [abstract 615] 14th conference on Retroviruses and opportunistic infections, 25-28 February 2007; Los Angeles, USA
13. McCutchan FE Global epidemiology of HIV J Med Virol 2006, 78(Suppl 1):S7-S12. 10.1002/jmv.20599 16622870
14. Damond F Bénard A on behalf of the ACHIeV2e study group Quality control assessment of HIV-2 viral load quantification assays: Results from an international collaboration on HIV-2 infection, 2006 [Abstract 676] 14th conference on Retroviruses and opportunistic infections, 25-28 February 2007; Los Angeles, USA
15. Rodés B Sheldon J Toro C Cuevas L Pérez-Pastrana E Herrera I Soriano V Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1) J Clin Microbiol 2007, 45:88-92. 1828987 17093034 10.1128/JCM.01613-06
16. Jallow S Kaye S Alabi A Aveika A Sarge-Njie R Sabally S Corrah T Whittle H Vanham G Rowland-Jones S Janssens W McConkey SJ Virological and immunolgical response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia AIDS 2006, 20:1455-1458. 10.1097/01.aids.0000233582.64467.8e 16791023
17. Matheron S Damond F Benard A Taieb A Campa P Peytavin G Pueyo S Brun-Vezinet F Chene G ANRS CO5 HIV2 Cohort Study Group CD4 cell recovery in treated HIV-2 infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort AIDS 2006, 20:459-462. 10.1097/01.aids.0000199829.57112.2f 16439883
18. Ndour CT Batista G Manga NM Guèye NF Badiane NM Fortez L Sow PS Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: Preliminary study Med Mal Infect 2006, 36:111-114. 16480843
19. van der Ende ME Prins JM Brinkman K Keuter M Veenstra J Danner SA Niesters HG Osterhaus AD Schutten M Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients AIDS 2003, (Suppl 3):S55-S61.
20. Houston SC Miedzinski LJ Mashinter LD Rapid progression of CD4 cell decline and subsequent response to salvage therapy in HIV-2 infection AIDS 2002, 16:1189-1191. 10.1097/00002030-200205240-00016 12004281
21. Mullins C Eisen G Popper S Dieng Sarr A Sankale JL Berger JJ Wright SB Chang HR Coste G Cooley TP Rice P Skolnik PR Sullivan M Kanki PJ Highly active antiretroviral therapy and viral response in HIV type 2 infection Clin Infect Dis 2004, 38:1771-1779. 10.1086/421390 15227626
22. Macneil A Sankale JL Meloni ST Sarr AD Mboup S Kanki P Long-Term Intrapatient Viral Evolution during HIV-2 Infection J Infect Dis 2007, 195:726-733. 10.1086/511308 17262716
23. Pieniazek D Rayfield M Hu DJ Nkengasong JN Soriano V Heneine W Zeh C Agwale SM Wambebe C Odama L Wiktor SZ HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1 AIDS 2004, 18:495-502. 10.1097/ 00002030-200402200-00016 15090802
24. Colson P Henry M Tivoli N Gallais H Gastaut JA Moreau J Tamalet C Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France J Med Virol 2005, 75:381-390. 10.1002/jmv.20296 15648062
25. BenM'Barek N Audoly G Raoult D Gluschankof P HIV-2 Protease resistance defined in yeast cells Retrovirology 2006, 3:58. 1570497 16956392 10.1186/1742-4690-3-58
26. Damond F Brun-Vezinet F Matheron S Peytavin G Campa P Pueyo S Mammano F Lastere S Farfara I Simon F Chene G Descamps D Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2 infected patients treated with protease inhibitors J Clin Microb 2005, 43:484-487. 10.1128/ JCM.43.1.484-487.2005
27. Colson P Henry M Tourres C Lozachmeur D Gallais H Gastaut JA Moreau J Tamalet C Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in southern France J Clin Microb 2004, 42:570-577. 10.1128/JCM.42.2.570-577.2004
28. Brandin E Lindborg L Gyllenstein K Broström C Hagberg L Gisslen M Tuvesson B Blaxhult A Albert J pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy AIDS Res Hum Retrovir 2003, 7:543-550. 10.1089/088922203322230905
29. Damond F Matheron S Peytavin G Campa P Taieb A Collin G Delaunay C Chêne G Brun-Vézinet F Descamps D Selection of K65R mutation in HIV-2 infected patients receiving tenofovir-containing regimen Antivir Ther 2004, 9:635-636. 15456096
30. Descamps D Damond F Matheron S Collin G Campa P Delarue S Pueyo S Chêne G Brun-Vézinet F French ANRS HIV-2 Cohort Study Group High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen J Med Virol 2004, 74:197-201. 10.1002/jmv.20174 15332266
31. Rodés B Holguin A Soriano V Dourana M Mansinho K Antunes F González-Lahoz J Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy J Clin Microbiol 2000, 38:1370-1374. 86447 10747109
32. van der Ende ME Guillon C Boers PH Ly TD Gruters RA Osterhaus AD Schutten M Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy J Acquir Immune Defic Syndr 2000, 25:11-18. 10.1097/ 00042560-200009010-00002 11064499
33. Ruelle J Sanou M Liu HF Vandenbroucke AT Duquenne A Goubau P Genetic Polymorphisms and Resistance Mutations of HIV Type 2 in Antiretroviral-Naive Patients in Burkina Faso AIDS Res Hum Retroviruses 2007, 23:955-964. 10.1089/aid.2007.0034 17725411
34. Ruelle J Kabamba Mukadi B Schutten M Goubau P Quantitative real-time PCR on Lightcycler® for the detection of human immunodeficiency virus type 2 (HIV-2) J Virol Meth 2004, 17:67-74. 10.1016/ j.jviromet.2003.12.006
35. Van Kerckhoven I Fransen K Peeters M De Beenhouwer H Piot P van der Groen GJ Quantification of human immunodeficiency virus in plasma by RNA PCR, viral culture, and p24 antigen detection J Clin Microbiol 1994, 32:1669-1673. 263757 7929756
36. Ghys PD Fransen K Diallo MO Ettiègne-Traoré V Coulibaly IM Yeboué KM Kalish ML Maurice C Whitaker JP Greenberg AE Laga M The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire AIDS 1997, 11:F85-93. 10.1097/00002030-199712000-00001 9342059
37. Matheron S Pueyo S Damond F Simon F Leprêtre A Campa P Salamon R Chêne G Brun-Vezinet F French HIV-2 Cohort Study Group Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort AIDS 2003, 17:2593-2601. 10.1097/ 00002030-200312050-00006 14685053
38. Humphrey JH Nathoo KJ Hargrove JW Iliff PJ Mutasa KE Moulton LH Chidawanyika H Malaba LC Zijenah LS Zvandasara P Ntozini R Zunguza CD Ward BJ the ZVITAMBO Study Group HIV-1 and HIV-2 prevalence and associated risk factors among postnatal women in Harare, Zimbabwe Epidemiol Infect 2007, 135:933-942. 10.1017/S0950268806007709 17217549
39. Ferns RB Garson JA Development and evaluation of a real-time RT-PCR assay for quantification of cell-free human immunodeficiency virus type 2 using a Brome Mosaic Virus internal control J Virol Methods 2006, 135:102-108. 10.1016/j.jviromet.2006.02.005 16563526
40. Braun J Plantier JC Hellot MF Tuaillon E Gueudin M Damond F Malmsten A Corrigan GE Simon F A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes AIDS 2003, 17:331-336. 10.1097/00002030-200302140-00006 12556686
41. Damond F Gueudin M Pueyo S Farfara I Robertson DL Descamps D Chène G Matheron S Campa P Brun-Vézinet F Simon F Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections J Clin Microbiol 2002, 40:3654-3659. 130845 12354861 10.1128/JCM.40.10.3654-3659.2002
42. Schutten M van den Hoogen B van der Ende ME Gruters RA Osterhaus AD Niesters HG Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma J Virol Methods 2000, 88:81-87. 10.1016/ S0166-0934(00)00177-4 10921845
43. Gottlieb GS Sow PS Hawes SE Ndoye I Redman M Coll-Seck AM Faye-Niang MA Diop A Kuypers JM Critchlow CW Respess R Mullins JI Kiviat NB Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa J Infect Dis 2002, 185:905-914. 10.1086/339295 11920314
44. Gustchina A Weber IT Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases Proteins 1991, 10:325-339. 10.1002/prot.340100406 1946342
45. Popper SJ Sarr AD Gueye-Ndiaye A Mboup S Essex ME Kanki PJ Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: Low virus production in vivo J Virol 2000, 74:1554-1557. 111493 10627569 10.1128/JVI.74.3.1554-1557.2000
46. Parreira R Monteiro F Padua E Piedade J Venenno T Paixão MT Esteves A Natural polymorphisms of HIV type 2 pol sequences from drug-naive individuals AIDS Res Hum Retroviruses 2006, 22:1178-1182. 10.1089/aid.2006.22.1178 17147507
47. Ruelle J Kabamba Mukadi B Delferrière N Goubau P Selection of resistance mutations in Human Immunodeficiency Virus type 2 (HIV-2) protease and reverse transcriptase [Abstract PE7.8/1] 10th European AIDS Conference/EACS, 17-20 November 2005, Dublin, Ireland
48. Perach M Rubinek T Hizi A Resistance to nucleoside analogs of selective mutants of human immunodeficiency virus type 2 reverse transcriptase J Virol 1995, 69:509-512. 188600 7527086
49. Rodés B Toro C Sheldon JA Jiménez V Mansinho K Soriano V High rate of proV47A selection in patients failing lopinavir-based HAART AIDS 2006, 20:127-129. 16327332